Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2021
Reporting Period: Event-based report regarding a specific corporate announcement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a regulatory disclosure regarding a clinical trial update rather than a financial report.
Material Changes
Clinical Trial Update: The Company announced its intention to present interim data from its Phase 1 clinical trial of OTX-TKI, an axitinib intravitreal implant. The trial targets patients with wet age-related macular degeneration and other retinal diseases.
Guidance, Outlook, and Management Commentary
- Event: Data presentation scheduled for the Angiogenesis, Exudations, and Degeneration 2021 Meeting.
- Timing: The meeting is held virtually on February 12 and February 13, 2021.
- Disclosure Status: Certain information to be presented is furnished as Exhibit 99.1. The Company explicitly states this information is not "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 for the specific interim data slides regarding the OTX-TKI Phase 1 trial.
- Confirm the schedule and access details for the Angiogenesis, Exudations, and Degeneration 2021 Meeting.
- Note that the data presented is interim and subject to the limitations described in the filing regarding legal liability.